Rémi Quirion became Québec’s first Chief Scientist in 2011. He is also leading the Fonds de recherche du Québec (FRQ) and advises the Ministère de l’Économie, Science et de l’Innovation (MESI) concerning the development of science and research in order to make sure of Québec’s position and influence in Canada and internationally. He takes care of developing intersectoral research. Furthermore, he is the Chairman of the three Fonds de recherche du Québec’s Boards of Directors and directs them alongside of their Scientific Directors. Prior to being the Québec’s Chief Scientist, Rémi Quirion was a Professor in the Department of Psychiatry at McGill University and Scientific Director at the Douglas Mental Health University Institute, to then become Vice-Dean at McGill University.
He is one of the most cited neuroscientists in the world and has received multiple awards and honors, such as the Ordre national du Québec (Chevalier du Québec, CQ) in 2003, the Prix Wilder-Penfield (Prix du Québec) in 2004, also the Order of Canada (OC) in 2007. In addition, Rémi Quirion was the first Scientific Director of the Institute of Neurosciences, Mental Health and Addiction (INMHA). To add to his accomplishments, he is also on the advisory board of more than 15 scientific journals in psychiatry, pharmacology, and neurosciences.
“It is withgreat enthusiasm thatwe welcomeRémi Quirion at our Board of directors. His vision of the life science ecosystem and his leadership will bring a significant contribution to our Board”, said Richard Fajzel, Chairman of CQDM’s Board of Directors.
"We are thrilled with the perspective to work with Rémi at CQDM. He has a great talent to bring people together and is very much engaged in our ecosystem. His presence will make a real difference at CQDM", said DianeGosselin, President and CEO ofCQDM.
CQDM is an industrial research cluster whose purpose is to allow Quebec companies to access the innovation research network in the biopharmaceutical sector. CQDM's business model is based on a collaborative approach where all partners share the costs of biopharmaceutical research. CQDM is also the catalyst where academia, governments, the pharmaceutical industry, and the biotechnology industry converge to create practical solutions to complex medical challenges. CQDM receives financial support from Merck, Pfizer Inc., AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Eli Lilly Canada, Janssen, Novartis Pharma Canada, Sanofi Canada, Servier, the Quebec Ministère de l’Économie, de la Science et de l’Innovation (MESI), and the Government of Canada (Business-led Networks of Centres of Excellence Program, or BL-NCE). Information: www.cqdm.org.
President and CEO, CQDM
Tel.: (514) 594-7286